131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging
Top Cited Papers
Open Access
- 20 July 2010
- journal article
- practice guideline
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (12) , 2436-2446
- https://doi.org/10.1007/s00259-010-1545-7
Abstract
The aim of this document is to provide general information about mIBG scintigraphy in cancer patients. The guidelines describe the mIBG scintigraphy protocol currently used in clinical routine, but do not include all existing procedures for neuroendocrine tumours. The guidelines should therefore not be taken as exclusive of other nuclear medicine modalities that can be used to obtain comparable results. It is important to remember that the resources and facilities available for patient care may vary from one country to another and from one medical institution to another. The present guidelines have been prepared for nuclear medicine physicians and intend to offer assistance in optimizing the diagnostic information that can currently be obtained from mIBG scintigraphy. The corresponding guidelines of the Society of Nuclear Medicine (SNM) and the Dosimetry, Therapy and Paediatric Committee of the EANM have been taken into consideration, and partially integrated into this text. The same has been done with the most relevant literature on this topic, and the final result has been discussed within a group of distinguished experts.Keywords
This publication has 39 references indexed in Scilit:
- Reply: 123I-MIBG Scintigraphy and 18F-FDG PET in NeuroblastomaJournal of Nuclear Medicine, 2010
- Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and ParagangliomaJournal of Clinical Endocrinology & Metabolism, 2009
- The Utility of Metaiodobenzylguanidine Single Photon Emission Computed Tomography/Computed Tomography (MIBG SPECT/CT) for the Diagnosis of PheochromocytomaAnnals of Surgical Oncology, 2009
- Comparison of Iodine-123 Metaiodobenzylguanidine (MIBG) Scan and [18F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therapy for Relapsed NeuroblastomaJournal of Clinical Oncology, 2009
- Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastomaPediatric Blood & Cancer, 2006
- Diagnosis of pheochromocytoma using [123I]‐ compared with [131I]‐metaiodobenzylguanidine scintigraphyInternational Journal of Urology, 1999
- Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumoursEuropean Journal Of Cancer, 1996
- A new 123I-MIBG whole body scan scoring method—Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastomaEuropean Journal Of Cancer, 1995
- Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomographyThe British Journal of Radiology, 1992
- Radiochemistry, biochemistry, and kinetics of 131I‐metaiodobenzylguanidine (MIBG) and 123I‐MIBG: Clinical implications of the use of 123I‐MIBGMedical and Pediatric Oncology, 1987